Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2024 Aug 5.
Published in final edited form as: Tetrahedron Lett. 2016 Jan 12;57(8):864–867. doi: 10.1016/j.tetlet.2016.01.036

Three-component reductive alkylation of 2-hydroxy-1, 4-naphthoquinones with lactols

Eliana E Kim 1, Evans O Onyango 1, Jennifer R Pace 1, Timothy M Abbot 1, Liangfeng Fu 1, Gordon W Gribble 1,*
PMCID: PMC11299892  NIHMSID: NIHMS1956246  PMID: 39105101

Abstract

Lactols II, obtained by DIBAL reduction of their corresponding lactones I, in equilibrium with their hydroxyaldehyde tautomers III were used in a three-component reductive alkylation with 2-hydroxy-1,4-naphthoquinone to give a series of 3-alkylated 2-hydroxy-1,4-naphthoquinone derivatives IV.

Keywords: Three-component reductive alkylation, Lactol, Hydroxyaldehyde, Naphthoquinone, Malaria


We recently reported the synthesis of monofluorinated 3-alkyl-2-hydroxy-1,4-naphthoquinone 1 by the l-proline-catalyzed three-component reductive alkylation (TCRA) of 2-hydroxy-1,4-naphthoquinone (2) with chiral aldehyde 3 (Fig. 1).1 Fluorinated 12 has been touted as a potential anti-malarial compound that could enhance the species selectivity and metabolic stability of atovaquone and other inhibitors of the cytochrome bc1 complex of the malaria parasite Plasmodium falciparum.3

Figure 1.

Figure 1.

Previous synthesis of monofluorinated 3-alkyl-2-hydroxy-1,4-naphthoquinone 1.

Following our enantioselective synthesis of 1 and for the purpose of determining its enantiomeric excess in order to support further biological assays, we needed to synthesize the racemic mixture for comparison. We had initially planned to utilize the chemistry already established. However, despite literature precedence for α-methylation of methyl esters,4 our attempts to alkylate (LDA or NaHMDS/MeI) the methyl ester 71 failed to provide sufficient quantities of 8 (Scheme 1).

Scheme 1.

Scheme 1.

Attempted α-methylation of fluoro methyl ester 7.

As an alternative, we synthesized the lactone 9 in 70% yield by treating 8-bromooctanoic acid (4) with TBAF·3H2O in tert-butanol at 70 °C overnight (Scheme 2). The trace amount of the 8-fluorooctanoic acid side product from this reaction was easily removed by column chromatography. While the tetra-n-butyl-ammonium fluoride trihydrate (TBAF·3H2O)-induced esterification of halo carboxylic acids has been reported in the literature,5,6 this is the first time oxonan-2-one (9) has been synthesized by this methodology. Furthermore, our new synthesis of 9 is much more efficient than the literature methods.7,8 For example, the synthesis of 9 using m-CPBA required extended reaction times9 (1–14 days) and were often complicated by the removal of unreacted starting material that has a nearly identical TLC Rf and boiling point to the product. Also, other Baeyer–Villiger oxidation procedures7 were equally encumbered by isolation and purification problems. With 9 in hand, α-methylation to afford 10 was achieved in 95% yield upon treatment of 9 with lithium diisopropyl amide (LDA) at −78 °C followed by the addition of MeI.10 Even though 3-methyloxonan-2- one (10) is a known compound, a recent article reporting on its thermodynamic properties did not provide details for its preparation.11 Next, partial DIBAL reduction of 10 gave hydroxyaldehyde 11 in equilibrium with a small amount of its lactol tautomer 12.

Scheme 2.

Scheme 2.

Synthesis and DIBAL reduction of lactone 10.

Subsequent l-proline-catalyzed three-component reductive alkylation of 2 and Hantzsch ester (5) gave lawsone derivative 13, a precursor to 1, in a yield of 89% (Scheme 3).1,12 This reaction mirrors the previously reported aldol reactions employing lactols in equilibrium with their hydroxyaldehydes.13,14

Scheme 3.

Scheme 3.

Synthesis of lawsone derivative 13.

To expand the scope of this reaction, other lactones 14–18 were either obtained from commercial sources or synthesized from their corresponding cycloketones via standard m-CPBA oxidation. Methylated lactones were also either commercially available or synthesized via literature procedures (Table 1, entries 47 and 515) using LDA or NaHMDS with MeI. The TCRA reaction of DIBAL products from these lactones proceeded smoothly to furnish 2-hydroxy-1,4-naphthoquinones. Representative examples, 19–24,16,17 are summarized in Table 1. In general, DIBAL reduction of small ring lactones (butyro- and valerolactone) (Table 1, entries 1 and 2) predominantly gave the lactol tautomer. In contrast, large ring lactones favored the hydroxyaldehyde tautomer upon DIBAL reduction. These results are in complete agreement with literature observations.18 In all cases, a two-to-one equivalent ratio of the lactol II or hydroxyaldehyde III to the 2-hydroxy-1,4-hydroxynaphthoquinone (2) was crucial for complete alkylation (Scheme 4). Regardless of the tautomeric equilibrium composition of the DIBAL reduction products, the reactions were all high yielding. Also, whereas the reaction proceeded slowly at room temperature, refluxing in CH2Cl2 not only dramatically improved the yield, but also prevented the tetrahydropyranylation or tetrahydrofuranylation of the terminal hydroxyl group (vide infra entry 1).

Table 1.

3-Alkyl-2-hydroxy-1,4-naphthoquinone derivatives

Entry Lactone Product Yield
1 graphic file with name nihms-1956246-t0001.jpg graphic file with name nihms-1956246-t0002.jpg 89a
graphic file with name nihms-1956246-t0003.jpg 77b
2 graphic file with name nihms-1956246-t0004.jpg graphic file with name nihms-1956246-t0005.jpg 95a
3 graphic file with name nihms-1956246-t0006.jpg graphic file with name nihms-1956246-t0007.jpg 87a
4 graphic file with name nihms-1956246-t0008.jpg graphic file with name nihms-1956246-t0009.jpg 74b
5 graphic file with name nihms-1956246-t0010.jpg graphic file with name nihms-1956246-t0011.jpg 91a
6 graphic file with name nihms-1956246-t0012.jpg graphic file with name nihms-1956246-t0013.jpg 88a
7 graphic file with name nihms-1956246-t0014.jpg graphic file with name nihms-1956246-t0015.jpg 89a
a

These reactions were refluxed.

b

These reactions were run at room temperature.

Scheme 4.

Scheme 4.

General synthetic approach to lawsone derivatives.

We also note that the yield from the alkylation reaction with butyrolactol was lower for the room temperature reaction and this was attributed to tetrahydrofuranylation of the terminal hydroxyl group (Table 1, entry 1). The same result was observed, to a smaller extent, with valerolactol. The masking of the terminal hydroxyl group leading to the formation of 20 was not surprising considering the fact that the TCRA reaction employed 2 equiv of the lactol/hydroxyaldehyde in an acidic reaction medium. Thus, after the initial reductive alkylation reaction, the terminal hydroxyl reacts with either excess lactol or its hydroxyaldehyde tautomer to form 20. However, at elevated temperatures the rate of hydrolysis (reverse reaction) is probably faster than that of tetrahydrofuranylation. We attempted to slow down tetrahydrofuranylation by reducing the aldehyde equivalents; however, in all cases a one-to-one ratio of aldehyde to hydroxynaphthoquinone 2 did not afford complete reaction even with extended reaction times. In any case, the overall yields of 19 and 21 could be improved by acid hydrolysis of their corresponding THP or THF ethers. Furthermore, because the products from TCRA reactions contain both enolic and terminal hydroxyl groups, selective masking of the terminal hydroxyl group is a serendipitous outcome that could potentially be utilized to achieve further synthetic modifications on these molecules.

In summary, we have synthesized 3-alkyl-2-hydroxy-1,4-naphthoquinone 13, a precursor to (±)1, in 3 steps from commercially available 8-bromooctanoic acid. Interest19,20 in lawsone (2-hydroxy-1,4-naphthoquinone) derivatives with 3-alkyl side chains ending in OH or other functional groups has increased following the seminal publication by Machatzke et al.21,22 These derivatives are potential inhibitors of various parasites including Plasmodium falciparum. Our work therefore not only provides a known 2-hydroxy-1,4-naphthoquinone derivative22 but also intermediates that could potentially be converted to known compounds.1921

Acknowledgments

E.E.K. acknowledges support from the Zabriskie Fellowship Fund at Dartmouth College, and J.R.P. had an iSURF fellowship. This work was supported in part by the Donors of the Petroleum Research Fund administered by the American Chemical Society, and in part by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103506.

Footnotes

Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.tetlet.2016.01.036.

References and notes

  • 1.Kim EE; Onyango EO; Fu L; Gribble GW Tetrahedron Lett. 2015, 56, 6707–6710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Hughes LM; Covian R; Gribble GW; Trumpower BL Biochim. Biophys. Acta 2010, 1797, 38–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kessl JJ; Moskalev NV; Gribble GW; Nasr M; Meshnick SR; Trumpower BL Biochim. Biophys. Acta 2007, 1767, 319–326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Dickschat JS; Bruns H; Riclea R Beilstein J. Org. Chem 2011, 7, 1697–1712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ooi T; Sugimoto H; Doda K; Maruoka K Tetrahedron Lett. 2001, 42, 9245–9248. [Google Scholar]
  • 6.Wu C; Brik A; Wang S; Chen Y; Wong C ChemBioChem 2005, 6, 2176–2180. [DOI] [PubMed] [Google Scholar]
  • 7.Lei Z; Ma G; Wei L; Yang Q; Su B Catal. Lett 2008, 125, 330–333. [Google Scholar]
  • 8.Van der Mee L; Helmich F; de Bruijin R; Vekemans JAJM; Palmans ARA; Meijer EW Macromolecules 2006, 39, 5021–5027. [Google Scholar]
  • 9.Koopmans C; Iannelli M; Kerep P; Klink M; Schmitz S; Sinnwell S; Ritter H Tetrahedron 2006, 62, 4709–4724. [Google Scholar]
  • 10.Temme O; Taj S; Andersson PG J. Org. Chem 1998, 63, 6007–6015. [DOI] [PubMed] [Google Scholar]
  • 11.Stepurko E; Roganov G Fibre Chem. 2015, 2, 80–89. [Google Scholar]
  • 12.Ramachary DB; Jain S Org. Biomol. Chem 2011, 9, 1277–1300. [DOI] [PubMed] [Google Scholar]
  • 13.Masuyama Y; Kobayashi Y; Kurusu YJ Chem. Soc., Chem. Commun 1994, 1123. [Google Scholar]
  • 14.Tomooka K; Okinaga T; Suzuki K; Tsuchihashi G Tetrahedron Lett. 1987, 28, 6335–6338. [Google Scholar]
  • 15.Arnold W; Mohr P Synlett 1996, 1215–1217. [Google Scholar]
  • 16.General Procedure for the TCRA reaction. A mixture of the DIBAL reduction product (lactol/hydroxyaldehyde) (2 equiv), 2-hydroxy-1,4-naphthoquinone (1 equiv), the Hantzsch ester (1 equiv), and l-Proline (0.5 equiv) in CH2Cl2 (0.3 M) was refluxed overnight. After cooling to room temperature, SiO2 was added to the reaction mixture, which was then concentrated in vacuo, and purified via dry-pack column chromatography to afford the final product.
  • 17. Compound 13. Yellow solid (89%). Mp 98 °C. Rf = 0.50 (1:1 hexanes/ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 8.08–8.13 (dd, J = 7.53, 0.97 Hz, 1H), 8.08–8.09 (dd, J = 7.53, 0.97 Hz, 1H), 7.74–7.77 (td, J = 7.57, 1.19 Hz, 1H), 7.67–7.70 (td, J = 7.57, 1.19 Hz, 1H), 7.32 (br s, 1H), 3.63–3.65 (t, J = 6.55 Hz, 2H), 2.59–2.62 (dd, J = 12.39, 6.29 Hz, 1H), 2.43–2.46 (dd, J = 12.39, 8.53 Hz, 1H), 1.82–1.85 (m, 1H), 1.54–1.59 (m, 2H), 1.22–1.42 (m, 8H), 0.88–0.89 (d, J = 6.89 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 185.1, 181.6, 153.8, 135.1, 133.2, 133.1, 129.7, 127.1, 126.3, 124.3, 63.3, 37.4, 31.0, 27.2, 20.0. FT-IR (CH2Cl2, cm−1) estim. 3360, 2930, 2850, 1640, 1590, 1460, 1370, 1270, 1220, 1020, 730. HRMS (ESI) calcd for C19H23O4: 315.1596, found 315.1593. Compound 19. Yellow solid (89%). Mp 143–144 °C. Rf = 0.40 (1:1 hexanes/ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 8.11–8.13 (dd, J = 7.42, 0.90 Hz, 1H), 8.09–8.08 (dd, J = 7.63, 0.90 Hz, 1H), 7.74–7.78 (td, J = 7.56, 1.33 Hz, 1H), 7.67–7.70 (td, J = 7.60, 1.33 Hz, 1H), 7.34 (br s, 1H), 3.70 (t, J = 6.15 Hz, 2H), 2.65 (t, J = 7.27 Hz, 2H), 1.66–1.26 (m, 4H). 13C NMR (150 MHz, CDCl3) δ 185.0, 181.6, 153.4, 135.1, 133.2, 133.1, 129.7, 127.0, 126.3, 124.5, 62.9, 32.6, 24.6, 23.0. FT-IR (CH2Cl2, cm−1) estim. 2920, 2360, 2340, 1630, 1590, 1460, 1350, 1210, 1070, 720. HRMS (ESI) calcd for C14H13O4: 245.0814, found 245.0811. Compound 20. Yellow solid (77%). Mp 84 °C. Rf = 0.70 (1:1 hexanes/ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 8.09 (ddd, J = 20.0, 9.0, 2.0 Hz, 2H), 7.71 (dtd, J = 36.0, 8.0, 2.0 Hz, 2H), 7.32–7.43 (br s, 1H), 5.10 (dd, J = 5.0, 2.0 Hz, 1H), 3.80–3.92 (m, 2H), 3.53 (ddt, J = 142.5, 9.5, 6.0 Hz), 2.59–2.67 (m, 2H), 1.74–2.06 (m, 4H), 1.54–1.72 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 184.9, 181.7, 153.4, 135.1, 133.2, 133.1, 129.7, 127.0, 126.3, 124.6, 104.0, 67.2, 67.0, 32.5, 29.9, 25.2, 23.7, 23.3. Compound 21. Yellow solid (95%). Mp 97–99 °C. Rf = 0.50 (1:1 hexanes/ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 8.11–8.13 (dd, J = 7.65, 0.93 Hz, 1H), 8.07–8.08 (dd, J = 7.54, 1.21 Hz, 1H), 7.74–7.77 (td, J = 7.45, 1.40 Hz, 1H), 7.66–7.70 (td, J = 7.45, 1.21 Hz, 1H), 7.34 (br s, 1H), 3.64–3.67 (t, J = 6.37 Hz, 2H), 2.61–2.64 (t, J = 7.66 Hz, 2H), 1.42–1.65 (m, 6H). 13C NMR (150 MHz, CDCl3) δ 185.0, 181.7, 153.3, 135.1, 133.2, 133.1, 129.7, 127.0, 126.3, 124.7, 63.1, 32.7, 28.2, 26.0, 23.4. FT-IR (CH2Cl2, cm−1) estim. 3350, 2930, 2860, 1670, 1640, 1590, 1460, 1370, 1270, 1210, 1020, 720. HRMS (ESI) calcd for C15H15O4: 259.0970, found 259.0969. Compound 22. Yellow solid (87%). Mp 104 °C. Rf = 0.45 (1:1 hexanes/ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 8.11–8.13 (dd, J = 7.62, 0.86 Hz, 1H), 8.07–8.09 (dd, J = 7.59, 0.89 Hz, 1H), 7.74–7.77 (td, J = 7.51, 1.30 Hz, 1H), 7.67–7.70 (td, J = 7.54, 1.20 Hz, 1H), 7.29 (br s, 1H), 3.63–3.65 (t, J = 6.51 Hz, 2H), 2.60–2.62 (t, J = 7.65 Hz, 2H), 1.40–1.59 (m, 8H). 13C NMR (150 MHz, CDCl3) δ 185.0, 181.7, 153.3, 135.1, 133.2, 133.1, 129.7, 127.0, 126.3, 124.9, 63.2, 32.9, 29.6, 28.4, 25.7, 23.4. FT-IR (CH2Cl2, cm−1) estim. 3440, 2930, 1670, 1630, 1590, 1460, 1350, 1270, 1210, 1020, 720. HRMS (ESI) calcd for C16H17O4: 273.1127, found 273.1125. Compound 23. Thick brown oil (74%). 1H NMR (500 MHz, CDCl3) δ 8.07–8.11 (m, J = 10.0 Hz, 2H), 7.67–7.75 (dd, J = 35.5, 12.5 Hz, 2H), 7.40 (br s, 1H), 3.62–3.67 (m, 2H), 2.53–2.55 (m, 2H), 1.10–1.25 (m, 7H), 0.87–0.92 (d, J = 10.0 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 185.0, 181.7, 153.3, 135.1, 133.1, 129.7, 127.0, 126.3, 124.8, 63.5, 44.7, 34.8, 34.0, 32.0, 28.2, 27.9, 24.0. HRMS (ESI) calcd for C20H25O4: 329.1753, found 329.1746. Compound 24. Thick brown oil (91%). 1H NMR (500 MHz, CDCl3) δ 8.07–8.13 (dd, J = 24.52, 7.55 Hz, 2H), 7.67–7.76 (dt, J = 42.77, 7.68 Hz, 1H), 7.33 (br s, 1H), 3.65–3.70 (m, 2H), 2.57–2.60 (t, J = 7.74 Hz, 2H), 1.25–1.60 (m, 7H), 0.90–0.91 (d, J = 6.53 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 185.0, 181.7, 153.3, 135.1, 133.2, 133.1, 129.7, 127.0, 126.3, 124.9, 61.4, 40.3, 37.1, 29.4, 25.8, 23.6, 19.8. FT-IR (CH2Cl2, cm−1) estim. 3350, 2930, 1670, 1640, 1590, 1460, 1370, 1270, 1220, 1040, 730. HRMS (ESI) calcd for C17H19O4: 287.1283, found 287.1282. Compound 25. Yellow solid (88%). Mp 93 °C. Rf = 0.45 (1:1 hexanes/ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 8.12–8.13 (dd, J = 7.81, 0.89 Hz, 1H), 8.07–8.09 (dd, J = 7.60, 0.95 Hz, 1H), 7.74–7.77 (td, J = 7.62, 1.35 Hz, 1H), 7.67–7.69 (td, J = 7.52, 1.20 Hz, 1H), 7.29 (br s, 1H), 3.63–3.65 (t, J = 6.45 Hz, 2H), 2.59–2.61 (t, J = 7.53 Hz, 2H), 1.33–1.58 (m, 12H). 13C NMR (150 MHz, CDCl3) δ 185.0, 181.7, 153.4, 148.8, 134.9, 133.1, 133.0, 129.7, 126.9, 126.2, 125.0, 63.2, 32.9, 32.8, 32.6, 29.8, 29.5, 29.3, 28.3, 28.2, 25.8, 23.5. FT-IR (CH2Cl2, cm−1) estim. 3500, 3210, 2920, 2850, 2360, 2340, 1670, 1640, 1590, 1460, 1360, 1270, 1220, 1030, 720. HRMS (ESI) calcd for C18H21O4: 301.1440, found 301.1433.
  • 18.Valters RE; Flitsch W Ring-Chain Tautomerism; Plenum Press: New York, 1985. [Google Scholar]
  • 19.Lu X; Altharawi A; Gut J; Rosenthal PJ; Long TE ACS Med. Chem. Lett 2012, 3, 1029–1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Nasiri HR; Madej MG; Panisch R; Lafontaine M; Bats J; Lancaster C; Schwalbe HJ Med. Chem 2013, 56, 9530–9541. [DOI] [PubMed] [Google Scholar]
  • 21.Machatzke H; Vaughan WR; Warren CL; White GR J. Pharm. Sci 1967, 56, 86–91. [DOI] [PubMed] [Google Scholar]
  • 22.Machatzke H; Vaughan WR; Warren CL; White GR J. Pharm. Sci 1968, 57, 520–523. [DOI] [PubMed] [Google Scholar]

RESOURCES